Response of an aggressive periosteal aneurysmal bone cyst (ABC) of the radius to denosumab therapy

详细信息    查看全文

• 作者：Chantal Pauli (1)
  Bruno Fuchs (2)
  Christian Pfirrmann (3)
  Julia A Bridge (4)
  Silvia Hofer (5)
  Beata Bode (1)
  
• 关键词：Aneurysmal bone cyst ; FISH ; USP6 ; Denosumab
• 刊名：World Journal of Surgical Oncology
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：12
• 期：1
• 全文大小：624 KB
• 作者单位：Chantal Pauli (1)
  Bruno Fuchs (2)
  Christian Pfirrmann (3)
  Julia A Bridge (4)
  Silvia Hofer (5)
  Beata Bode (1)
  
  1. Institute of Surgical Pathology, University Hospital Zurich, CH-8091, Zurich, Switzerland
  2. Orthopedics, University Hospital Balgrist, Zurich, Switzerland
  3. Radiology, University Hospital Balgrist, Zurich, Switzerland
  4. Department of Pathology/Microbiology, University of Nebraska Medical Center, Omaha, NE, USA
  5. Oncology, University Hospital Zurich, Zurich, Switzerland
  
• ISSN：1477-7819

文摘

Aneurysmal bone cyst (ABC), once considered a reactive lesion, has been proven to be a neoplasia characterized by rearrangements of the USP6-gene. Aggressive local growth and recurrences are common and therapeutic options may be limited due to the vicinity of crucial structures. We describe a case of a locally aggressive, multinucleated giant cell-containing lesion of the forearm of a 21-year old woman, treated with denosumab for recurrent, surgically uncontrollable disease. Under the influence of this RANKL inhibitor, the tumor showed a marked reduction of the content of the osteoclastic giant cells and an extensive metaplastic osteoid production leading to the bony containment, mostly located intracortically in the proximal radius. The diagnosis of a periosteal ABC was confirmed by FISH demonstrating USP6 gene rearrangement on the initial biopsy. Function conserving surgery could be performed, enabling reconstruction of the affected bone. Inhibition of RANKL with denosumab may offer therapeutic option for patients not only with giant cell tumors but also with ABCs.